Dual action of miR-125b as a tumor suppressor and OncomiR-22 promotes prostate cancer tumorigenesis

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Budd, William T ^a   Seashols Williams, Sarah J ^a,b   Clark, Gene C ^a   Weaver, Danielle ^b   Calvert, Valerie ^c   Petricoin, Emanuel ^c   Dragoescu, Ema A ^d   O'Hanlon, Katherine ^e   Zehner, Zendra E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c GEORGE MASON UNIVERSITY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^e American International Biotechnology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MICRORNA 125B; MICRORNA 22; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; MICRORNA; MIRN125 MICRORNA, HUMAN; MIRN22 MICRORNA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; ONCOPROTEIN; TUMOR MARKER;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LASER CAPTURE MICRODISSECTION; LASER MICRODISSECTION; MALE; MICROARRAY ANALYSIS; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; ANIMAL; CYTOLOGY; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROTEOMICS; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; BIOMARKERS, TUMOR; CARCINOGENESIS; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE, NUDE; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATE; PROSTATIC NEOPLASMS; PROTEOMICS;

EID: 84952685375     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142373     Document Type: Article

References (56)

1. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006; 25: 6188-6196. PMID: 17028598
2. Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004; 5: 396-400. PMID: 15143321
3. Boehm M, Slack FJ. MicroRNA control of lifespan and metabolism. 2006; 5: 837-840.
4. Zhao Y, Srivastava D. A developmental view of microRNA function. Trends Biochem Sci. 2007; 32: 189-197. PMID: 17350266
5. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6: 259-269. PMID: 16557279
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281-297. PMID: 14744438
7. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103: 2257-2261. PMID: 16461460
8. DeVere White RW, Vinall RL, Tepper CG, Shi XB. MicroRNAs and their potential for translation in prostate cancer. Urol Oncol. 2009; 27: 307-311. PMID: 19414119
9. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101: 2999-3004. PMID: 14973191
10. Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev. 2006; 16: 4-9. PMID: 16361094
11. Budd WT, Weaver DE, Anderson J, Zehner ZE. MicroRNA dysregulation in prostate cancer: Network analysis reveals preferential regulation of highly connected nodes. Chem Biodivers. 2012; 9: 857-867. doi: 10.1002/cbdv.201100386 PMID: 22589088
12. Budd WT, Seashols S, Weaver D, Joseph C, Zehner ZE. A networks method for ranking microRNA dysregulation in cancer. BMC Syst Biol. 2013; 7 Suppl 5: S3-0509-0509-7-S5-S3. Epub 2013 Dec 9.
13. Bae VL, Jackson-Cook CK, Brothman AR, Maygarden SJ, Ware JL. Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. Int J Cancer. 1994; 58: 721-729. PMID: 8077059
14. Bae VL, Jackson-Cook CK, Maygarden SJ, Plymate SR, Chen J, Ware JL. Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line. Prostate. 1998; 34: 275-282. PMID: 9496902
15. Astbury C, Jackson-Cook CK, Culp SH, Paisley TE, Ware JL. Suppression of tumorigenicity in the human prostate cancer cell line M12 via microcell-mediated restoration of chromosome 19. Genes Chromosomes Cancer. 2001; 31: 143-155. PMID: 11319802
16. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001; 20: 1981-1989. PMID: 11360182
17. Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL, et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics. 2003; 3: 2142-2146. PMID: 14595813
18. Seashols S. Variation and modulation of microRNAs in prostate cancer and biological fluids. Phd Dissertation. Virginia Commonwealth University 2013.
19. Zhang X, Ladd A, Dragoescu E, Budd WT, Ware JL, Zehner ZE. MicroRNA-17-3p is a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate tumors analyzed by laser capture microdissection. Clin Exp Metastasis. 2009; 26: 965-979. doi: 10.1007/s10585-009-9287-2 PMID: 19771525
20. Espina V, Wulfkuhle JD, Calvert VS, VanMeter A, Zhou W, Coukos G, et al. Laser-capture microdissection. Nat Protoc. 2006; 1: 586-603. PMID: 17406286
21. Budd WT, Combinatorial analysis of tumorigenic microRNAs driving prostate cancer PhD Dissertation. Virginia Commonwealth University 2012.
22. Zhang X, Fournier M, Ware JL, Bissel MJ, Yacoub A, Zehner ZE. Inhibition of vimentin or ß1-integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol Cancer Ther. 2009; 8:499-508. doi: 10.1158/1535-7163.MCT-08-0544 PMID: 19276168
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-(ΔΔC(T)) Method. Methods. 2001; 25: 402-408. PMID: 11846609
24. Gleason DF, Mellinger G. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111: 58-64. PMID: 4813554
25. Paweletz CP, Liotta LA, Petricoin EF 3rd. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology. 2001; 57: 160-163. PMID: 11295617
26. Yee JY, Limenta LM, Rogers K, Rogers SM, Tay VS, Led EJ. Ensuring good quality RNA for quantitative real-time PCR isolated from renal proximal tubular cells using laser capture microdissection. BMC Res Notes 2014; 7: 62-69. doi: 10.1186/1756-0500-7-62 PMID: 24467986
27. Joseph A, Gnanapragasam VJ. Laser-capture microdissection and transcriptional profiling in archival FFPE tissue in prostate cancer. Methods Mol Biol. 2011; 755: 291-300. doi: 10.1007/978-1-61779-163-5-24 PMID: 21761313
28. Nonn L, Vaishnav A, Gallagher L, Gann PH. mRNA and micro-RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials. Exp Mol Pathol. 2010; 88: 45-51. doi: 10.1016/j.yexmp.2009.10.005 PMID: 19874819
29. Shukla CJ, Pennington CJ, Riddick AC, Sethia KK, Ball RY, Edwards DR. Laser-capture microdissection in prostate cancer research: establishment and validation of a powerful tool for the assessment of tumour-stroma interactions. BJU Int. 2008; 101; 765-74. doi: 10.1111/j.1464-410X.2007.07372.x PMID: 18190638
30. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2007; 282: 1479-1486. PMID: 17110380
31. Bar N, Dikstein R. miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One. 2010; 5: e10859. doi: 10.1371/journal.pone.0010859 PMID: 20523723
32. Wu Y, Zhang X, Zehner ZE. c-Jun and the dominant-negative mutant, TAM67, induce vimentin gene expression by interacting with the activator Sp1. Oncogene. 2003; 22: 8891-8901. PMID: 14654785
33. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. 1989; 2: 33-50. PMID: 2482772
34. Klink JC, Miocinovic R, Magi Galluzzi C, Klein EA. High-grade prostatic intraepithelial neoplasia. Korean J Urol. 2012; 53: 297-303. doi: 10.4111/kju.2012.53.5.297 PMID: 22670187
35. Bostwick DG, Liu L, Brawer MK, Qian J. High-grade prostatic intraepithelial neoplasia. Rev Urol. 2004; 6: 171-179. PMID: 16985598
36. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003; 100: 8933-8938. PMID: 12853564
37. Lu X, Kang Y. Epidermal growth factor signaling and bone metastasis. Br J Cancer. 2010; 102: 457-461. doi: 10.1038/sj.bjc.6605490 PMID: 20010942
38. Dubovenko A, Serebryiskaya T, Nikolsky Y, Nikolskaya T, Perlina A, JeBailey L, et al. Reconstitution of the ERG gene expression network reveals new biomarkers and therapeutic Targets in ERG positive prostate tumors. J Cancer. 2015; 6: 490-501. doi: 10.7150/jca.8213 PMID: 26000039
39. Priolo C, Pyne S, Rose J, Regan ER, Zadra G, Photopoulos C, et al. AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res. 2014; 74: 7198-7204. doi: 10.1158/0008-5472.CAN-14-1490 PMID: 25322691
40. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003; 4: 209-221. PMID: 14522255
41. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010; 11: 136-146. doi: 10.1016/S1470-2045(09)70343-2 PMID: 20022810
42. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol. 2009; 219: 214-221. doi: 10.1002/path.2586 PMID: 19593777
43. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297: 1901-1908. PMID: 17473300
44. Veerla S, Lindgren D, Kvist A, Frigyesi A, Staaf J, Persson H, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer. 2009; 124: 2236-2242. doi: 10.1002/ijc.24183 PMID: 19127597
45. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008; 111: 478-486. doi: 10.1016/j.ygyno.2008.08.017 PMID: 18823650
46. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011; 71: 3552-3562. doi: 10.1158/0008-5472.CAN-10-2435 PMID: 21444677
47. Chen D, Cabay RJ, Jin Y, Wang A, Lu Y, Shah-Khan M, et al. MicroRNA deregulations in head and neck squamous cell carcinomas. J Oral Maxillofac Res. 2013; 4: e2.
48. Li W, Xie L, He X, Li J, Tu K, Wei L, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer. 2008; 123: 1616-1622. doi: 10.1002/ijc.23693 PMID: 18649363
49. He J, Xu Q, Jing Y, Agani F, Qian X, Carpenter R, et al. Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation. EMBO Rep. 2012; 13: 1116-1122. doi: 10.1038/embor.2012.162 PMID: 23146892
50. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 2007; 104: 19983-19988. PMID: 18056640
51. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate. 2011; 71: 538-549. doi: 10.1002/pros.21270 PMID: 20886540
52. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TLJ, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007; 67: 6130-6135. PMID: 17616669
53. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010; 126: 1166-1176. doi: 10.1002/ijc.24827 PMID: 19676045
54. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008; 27: 1788-1793. PMID: 17891175
55. Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, et al. MicroRNA profiling in prostate cancer-the diagnostic potential of urinary miR-205 and miR-214. PLoS One. 2013; 8:e76994. doi: 10.1371/journal.pone.0076994 PMID: 24167554
56. Kruger J, Rehmsmeier M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res. 2006; 34: W451-4. PMID: 16845047